Pub. Date : 2009 Nov
PMID : 19891554
9 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 2 | Impaired metabolism of sulfonylureas due to gene polymorphisms in the metabolic enzyme CYP2C9 might lead to hypoglycemia. | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 3 | In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 4 | In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 5 | In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 6 | In a model adjusted for age, BMI, mean daily dose of sulfonylurea, duration of T2DM and renal function, CYP2C9*1/*3 genotype increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 1.687; p = 0.011). | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 7 | In a model adjusted for age, BMI, mean daily dose of sulfonylurea, duration of T2DM and renal function, CYP2C9*1/*3 genotype increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 1.687; p = 0.011). | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 8 | Furthermore, in T2DM patients, CYP2C9*3 increases the risk of hypoglycemia when they are treated with sulfonylureas, possibly due to impaired metabolism of these drugs. | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 9 | CYP2C9 genotyping might thus be a useful tool for predicting adverse effects caused by sulfonylureas and help clinicians in safer prescribing of oral hypoglycemic agents. | Sulfonylurea Compounds | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |